For type 2 diabetes mellitus. ANDA 212677, held by Vistapharm LLC. Metformin Hydrochloride.
As of Nov 16, 2026, ANDA 212677 (Metformin Hydrochloride), held by Vistapharm LLC, was first approved by FDA on Aug 19, 2022, with 1 approved supplement and 0 published complete response letters.
Metformin hydrochloride oral solution is indicated as an adjunct to diet and exercise to improve glycemic control in adults and pediatric patients 10 years of age and older with type 2 diabetes mellitus.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 19, 2022 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| Metformin Hydrochloride500MG/5ML · solution;oral | Metformin Hydrochloride | Rx |
| Aug 11, 2026 | Supplement 9Labeling · Standard review | Approved | None posted |
| Aug 19, 2022 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters